Company profile SPRO
There is not enough data for Spero Therapeutics profile to provide analysis
There is not enough data for Spero Therapeutics profile to provide correlation calculation
There is not enough data for Spero Therapeutics profile to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Spero Therapeutics news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 21 | 0 -100.0% QoQ | 60 inf% QoQ | 146 143.3% QoQ |
| 2020 | 158 652.4% YoY 8.2% QoQ | 134 inf% YoY -15.2% QoQ | 53 -11.7% YoY -60.4% QoQ | 22 -84.9% YoY -58.5% QoQ |
| 2021 | 62 -60.8% YoY 181.8% QoQ | 84 -37.3% YoY 35.5% QoQ | 19 -64.2% YoY -77.4% QoQ | 138 527.3% YoY 626.3% QoQ |
| 2022 | 151 143.5% YoY 9.4% QoQ | 126 50.0% YoY -16.6% QoQ | 139 631.6% YoY 10.3% QoQ | 18 -87.0% YoY -87.1% QoQ |
| 2023 | 73 -51.7% YoY 305.6% QoQ | 18 -85.7% YoY -75.3% QoQ | 20 -85.6% YoY 11.1% QoQ | 88 388.9% YoY 340.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Spero Therapeutics news was 5.86 per week. The last year interest of Spero Therapeutics news compared to the last 5 years has changed by -34.64%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -34.31%.
There is not enough data for multi-drug resistant bacterial infections to provide analysis
There is not enough data for multi-drug resistant bacterial infections to provide correlation calculation
There is not enough data for multi-drug resistant bacterial infections to provide analysis
After 39 days of this quarter the interest is at 141.0. Based on that we can calculate that during remaining 52 days it will total up to 329.0. rare diseases treatment expected interest is significantly higher compared to previous quarter (+196.4%) and same quarter last year (+186.1%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 43 | 70 62.8% QoQ | 151 115.7% QoQ | 50 -66.9% QoQ |
| 2020 | 172 300.0% YoY 244.0% QoQ | 90 28.6% YoY -47.7% QoQ | 100 -33.8% YoY 11.1% QoQ | 73 46.0% YoY -27.0% QoQ |
| 2021 | 107 -37.8% YoY 46.6% QoQ | 70 -22.2% YoY -34.6% QoQ | 28 -72.0% YoY -60.0% QoQ | 98 34.2% YoY 250.0% QoQ |
| 2022 | 138 29.0% YoY 40.8% QoQ | 160 128.6% YoY 15.9% QoQ | 79 182.1% YoY -50.6% QoQ | 74 -24.5% YoY -6.3% QoQ |
| 2023 | 115 -16.7% YoY 55.4% QoQ | 130 -18.8% YoY 13.0% QoQ | 164 107.6% YoY 26.2% QoQ | 111 50.0% YoY -32.3% QoQ |
| 2024 | 141 22.6% YoY 27.0% QoQ | - | - | - |
The average 5 years interest of rare diseases treatment was 8.29 per week. The last year interest of rare diseases treatment compared to the last 5 years has changed by 39.69%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 40.7%.
There is not enough data for tebipenem pivoxil hydrobromide to provide analysis
There is not enough data for tebipenem pivoxil hydrobromide to provide correlation calculation
There is not enough data for tebipenem pivoxil hydrobromide to provide analysis
There is not enough data for SPR206 Gram-negative bacterial infections to provide analysis
There is not enough data for SPR206 Gram-negative bacterial infections to provide correlation calculation
There is not enough data for SPR206 Gram-negative bacterial infections to provide analysis
There is not enough data for SPR720 non-tuberculous mycobacterial pulmonary disease to provide analysis
There is not enough data for SPR720 non-tuberculous mycobacterial pulmonary disease to provide correlation calculation
There is not enough data for SPR720 non-tuberculous mycobacterial pulmonary disease to provide analysis
There is not enough data for Meiji Seika Pharma license agreement to provide analysis
There is not enough data for Meiji Seika Pharma license agreement to provide correlation calculation
There is not enough data for Meiji Seika Pharma license agreement to provide analysis
There is not enough data for Everest Medicines collaboration to provide analysis
There is not enough data for Everest Medicines collaboration to provide correlation calculation
There is not enough data for Everest Medicines collaboration to provide analysis
There is not enough data for Bill & Melinda Gates Medical Research Institute partnership to provide analysis
There is not enough data for Bill & Melinda Gates Medical Research Institute partnership to provide correlation calculation
There is not enough data for Bill & Melinda Gates Medical Research Institute partnership to provide analysis
There is not enough data for Vertex Pharmaceuticals license agreement. to provide analysis
There is not enough data for Vertex Pharmaceuticals license agreement. to provide correlation calculation
There is not enough data for Vertex Pharmaceuticals license agreement. to provide analysis